ClinicalTrials.gg
TerminatedNCT03718533ELTIONUpdated Feb 29, 2024Results posted

Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function

A Phase 2 interventional study of Eltrombopag in Poor Graft Function, sponsored by Novartis Pharmaceuticals. Terminated at 7 sites in Spain. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-02-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
In the context of COVID-19 pandemic, the benefit / risk ratio of the participation of a patient with pancytopenia could be compromised. The decision of this premature termination was not the consequence of any safety reason inherent to the drug.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The purpose of this study was to evaluate the efficacy of eltrombopag for poor graft function (PGF) on overall hematologic response (partial and complete), as determined by platelet, hemoglobin and neutrophil counts by 16 weeks after the initiation of eltrombopag in patients with poor graft function after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Read the detailed description

This was an open-label, single-arm phase II study, in which participants diagnosed with PGF after allo-HSCT were treated with eltrombopag up to week 36 or until the participant's premature withdrawal.

The study consisted of the following periods:

  • Screening Period (baseline): the participant screening criteria was reviewed, and the procedures established in the evaluation schedule were performed.
  • Treatment Period: from administration of the first dose of eltrombopag until time when participant permanently stopped taking study treatment for any reason or until 36 weeks had passed. Eltrombopag was initiated on Day 1 at a dose of 150 mg once daily (75 mg daily in Asian ancestry participants). During the Treatment Period, participants were evaluated weekly during the first month, every 2 weeks during the next 2 months and subsequently every 4 weeks until week 24. For the last 3 months, participants were followed every 6 weeks Only participants who had a partial or complete response at Week 16 continued to receive eltrombopag up to Week 36 or until loss of response (defined as a decrease in blood counts to levels that did not continue to meet the criteria for response established in the protocol), unacceptable toxicity, or discontinuation for any other reason.

Participants who discontinued eltrombopag because efficacy, continued in the study and attended the scheduled visits of Treatment Period as per protocol. If loss of response occurred, eltrombopag was reintroduced at the last effective dose.

  • Final Visit (or Early Withdrawal): this visit took place 30 days after completion of the Treatment Period, or premature participant withdrawal.
  • Follow-up for Survival: all participants who discontinued from the study, regardless the reason of discontinuation, were followed for survival for 24 and 36 weeks, unless they withdrew their consent, died or were lost-to follow-up, in which case study visits were no longer carried out.
02

Conditions studied

  • Poor Graft Function

Keywords

  • Eltrombopag
  • Hematological response
  • Poor graft function
  • Stem cell transplantation
  • Adult
  • ELTION
  • Phase II
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be able to understand and communicate with the investigator and comply with the requirements of the study and must provide written, signed and dated form before any study assessment is performed
  2. Male of female patients ≥ 18 years of age
  3. Patients diagnosed with primary or secondary poor graft function (PGF) defined as two or more cytopenias after day +30 post-transplant (re-tested in a peripheral blood analysis at screening):

    1. count \<20,000/ µL (mandatory)
    2. (ANC) \<1,000/µL
    3. \<100 g/L
  4. Presence of donor chimerism >90% in screening visit
  5. status ≥90% (Karnofsky assessment must be performed within 7 days prior to Day 1)

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or nursing (lactating women).
  2. Evidence of active acute or chronic (GVHD).
  3. Evidence of any active .
  4. Subjects who are human immune deficiency virus (), virus (HCV), surface antigen (HBsAg) positive in screening visit.
  5. Cytogenetic abnormality in chromosome 7 present before the allo-HSC.
  6. Evidence of any clonal abnormality on cytogenetics (in bone marrow analysis).

    • A local post-transplant conventional cytogenetic assessment should be available within 8 weeks before Day 1.
    • If the cytogenetics is not valuable, i.e, it does not show metaphases, a FISH for MDS-related most frequent abnormalities including chromosome 7 is accepted.

    As a consequence, patients with dry tap bone marrow aspiration are NOT eligible.

  7. Evidence of bone marrow involvement or progression of the underlying disease assessed by the applicable methods in each case.
  8. Evidence of thrombotic microangiopathy.
  9. Evidence of possible causes of cytopenia other than PGF (active infections, myelotoxic drugs, hypersplenism...).
  10. Prior use of any thrombopoietin receptor (TPO-R) agonists for PGF.
  11. or ALT levels >3 x .
  12. Creatinine level ≥1.5 x ULN.
  13. Total level ≥1.5 x ULN.
  14. Previous thromboembolic event (other than line-related upper extremity thrombosis)
  15. to eltrombopag or its components.
  16. abnormality history or current diagnosis of cardiac disease indicating significant risk of safety for subjects participating in the study such as uncontrolled or significant cardiac disease or impaired cardiac function including any of the following:

    1. . Corrected > 450 msec (male subjects), > 460 msec (female subjects) using Fredericia correction (QTcF) on the screening ECG
    2. . Myocardial infarction
    3. . Uncontrolled congestive heart failure
    4. . Unstable angina
    5. . Congenital long QT syndrome.
  17. Administration of an drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment.
  18. Patient with liver cirrhosis.
  19. Risk factors for Torsade de Pointes including uncorrected hypokalemia or hypomagnesemia.
  20. Subjects with any serious and/ or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with patient´s safety, obtaining or compliance with the study procedures as per investigator discretion.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Eltrombopag

    Patients received eltrombopag orally once daily up to 36 weeks.

    Drug: Eltrombopag

Interventions

  • Eltrombopag was provided as 50 mg or 25 mg film-coated tablets for oral use administration

06

What researchers measure

Primary outcomes

  1. Hematologic Response Rate by 16 Weeks After the Initiation of Eltrombopag

    Hematologic response rate was defined as the percentage of participants who met the criteria of either complete response (CR) or partial response (PR) by Week 16. PR was defined when any of the following: Platelet count ≥ 20000/microliter(μL) (with platelet transfusion independence), absolute neutrophil count (ANC) ≥1000/μL (when pretreatment ANC was \<1000/μL) and/or hemoglobin (Hb) ≥100 gram(g)/ liter(L) (when pretreatment Hb was \<100g/L) (with red blood cells transfusion independence), confirmed in two blood tests separated a minimum of 7 days. CR was defined when all of the following: platelet count ≥100000/μL, ANC ≥1500/μL (when pretreatment ANC was \<1000/μL) and Hb ≥110 g/L (when pretreatment Hb was \<100g/L), confirmed in two blood tests separated a minimum of 7 days. Participants who discontinued before Week 16 were considered as responders if, in the last evaluation, they had PR or CR. The 95% Confidence Interval (CI) was the binomial exact CI based on Clopper-Pearson method.

    Time frame: Baseline up to Week 16

Secondary outcomes

  1. Percentage of Participants Who Had a Response in the Neutrophil Lineage

    Percentage of participants who had a response (partial or complete) in the neutrophil lineage. A partial response in the neutrophil lineage was defined as absolute neutrophil count (ANC) ≥1000/ µL (when pretreatment ANC was \<1000/μL) confirmed in two consecutive blood tests separated a minimum of 7 days. A complete response in the neutrophil lineage was defined as ANC ≥ 1500/ µL (when pretreatment ANC was \<1000/μL) confirmed in two consecutive blood tests separated a minimum of 7 days. The 95% CI was the binomial exact CI based on Clopper-Pearson method

    Time frame: Week 16, 20, 24, 30 and 36

  2. Percentage of Participants Who Had a Response in the Platelet Lineage

    Percentage of participants who had a response (partial or complete) in the platelet lineage. A partial response in the platelet lineage was defined as platelet count ≥20000/µL (with platelet transfusion independence) confirmed in two consecutive blood tests separated a minimum of 7 days. A complete response in the platelet lineage was defined as platelet count ≥ 100000/µL confirmed in two consecutive blood tests separated a minimum of 7 days. The 95% CI was the binomial exact CI based on Clopper-Pearson method.

    Time frame: Week 16, 20, 24, 30 and 36

  3. Percentage of Participants Who Had a Response in the Hemoglobin Lineage

    Percentage of participants who had a response (partial or complete) in the hemoglobin (Hb) lineage. A partial response in the Hb lineage was defined as Hb ≥100 g/L (when pretreatment Hb was \<100g/L) (with RBC transfusion independence), confirmed in two consecutive blood tests separated a minimum of 7 days. A complete response in the Hb lineage was defined as Hb≥ 110 g/L (when pretreatment Hb was \<100g/L) confirmed in two consecutive blood tests separated a minimum of 7 days. The 95% CI was the binomial exact CI based on Clopper-Pearson method.

    Time frame: Week 16, 20, 24, 30 and 36

  4. Hematologic Response Rate at Week 24 and 36

    Hematologic response rate was defined as the percentage of participants who met the criteria of either complete response (CR) or partial response (PR) at 24 weeks and 36 weeks after the initiation of eltrombopag. PR was defined when any of the following: Platelet count ≥20000/microliter (μL) (with platelet transfusion independence), absolute neutrophil count (ANC) ≥1000/μL (when pretreatment ANC was \<1000/μL) and/or hemoglobin (Hb) ≥100 gram (g)/ liter (L) (when pretreatment Hb was \<100g/L) (with red blood cells transfusion independence), confirmed in two blood tests separated a minimum of 7 days. CR was defined when all three of the following: platelet count ≥100000/μL, ANC ≥1500/μL (when pretreatment ANC was \<1000/μL) and Hb ≥110 g/L (when pretreatment Hb was \<100g/L), confirmed in two blood tests separated a minimum of 7 days. The 95% CI was the binomial exact CI based on Clopper-Pearson method.

    Time frame: Week 24 and 36

  5. Percentage of Participants Who Were Previously Platelet Transfusion-dependent and Did no Longer Require Platelet Transfusions After the Initiation of Eltrombopag

    Percentage of participants who received at least one platelet transfusion before starting treatment and who did no longer require platelet transfusion before and after the first 16 weeks of treatment. The 95% CI was the binomial exact CI based on Clopper-Pearson method.

    Time frame: From start of treatment to end of treatment, assessed up to 36 weeks

  6. Percentage of Participants Who Were Previously Red Blood Cells Transfusion-dependent and Did no Longer Require Red Blood Cells Transfusions

    Percentage of participants who received at least one red blood cells transfusion before starting treatment and who did no longer require red blood cells transfusion before and after the first 16 weeks of treatment. The 95% CI was the binomial exact CI based on Clopper-Pearson method.

    Time frame: From start of treatment to end of treatment, assessed up to 36 weeks

  7. Duration of Transfusion Independence

    Duration of transfusion independence defined as the period of time where participants did not receive any platelet or red blood cells transfusions during the treatment period

    Time frame: From start of treatment to end of treatment, assessed up to 36 weeks

  8. Percentage of Participants Who Discontinued or Reduced the Use of Concomitant Erythropoietin (EPO) Therapy

    Percentage of participants who discontinued or reduced by ≥50% from baseline the use of concomitant EPO therapy while receiving eltrombopag. The 95% CI was the binomial exact CI based on Clopper-Pearson method.

    Time frame: From start of treatment to end of treatment, assessed up to Week 36

  9. Percentage of Participants Who Discontinued or Reduced the Use of Concomitant Granulocyte Colony-stimulating Factor (G-CSF) Therapy

    Percentage of participants who discontinued or reduced by ≥50% from baseline the use of concomitant G-CSF therapy while receiving eltrombopag. The 95% CI was the binomial exact CI based on Clopper-Pearson method.

    Time frame: From start of treatment to end of treatment, assessed up to Week 36

  10. Overall Survival (OS)

    OS defined as the time from the date of inclusion until the date of death due to any cause was calculated using Kaplan-Meier estimated. All patients who discontinued from the study, regardless the reason of discontinuation, were followed for survival, unless they withdrew their consent, died or were lost-to follow-up, in which case were censored at the last contact.

    Time frame: From start of treatment until the date of death, assessed up to 40 weeks

  11. Overall Survival Rate at 24 and 36 Weeks

    Overall survival rate defined as the rate estimate of the percentage of participants who were alive at 24 and 36 weeks. All patients who discontinued from the study, regardless the reason of discontinuation, were followed for survival at Week 24 and 36, unless they withdrew their consent, died or were lost-to follow-up, in which case were censored at the last contact.

    Time frame: Week 24 and 36

07

Results

Posted Feb 5, 2024

Participant flow

The study was conducted across 7 centers in 1 country (Spain).

Participant flow — Overall Study
MilestoneEltrombopag
Started10
Completed3
Not completed7
Withdrew: Myelodysplastic syndrome and study indication1
Withdrew: Protocol deviation1
Withdrew: Disease progression1
Withdrew: Relapse1
Withdrew: Physician decision2
Withdrew: Physician decision and adverse event1

Outcome measures

PrimaryHematologic Response Rate by 16 Weeks After the Initiation of Eltrombopag

Hematologic response rate was defined as the percentage of participants who met the criteria of either complete response (CR) or partial response (PR) by Week 16. PR was defined when any of the following: Platelet count ≥ 20000/microliter(μL) (with platelet transfusion independence), absolute neutrophil count (ANC) ≥1000/μL (when pretreatment ANC was \<1000/μL) and/or hemoglobin (Hb) ≥100 gram(g)/ liter(L) (when pretreatment Hb was \<100g/L) (with red blood cells transfusion independence), confirmed in two blood tests separated a minimum of 7 days. CR was defined when all of the following: platelet count ≥100000/μL, ANC ≥1500/μL (when pretreatment ANC was \<1000/μL) and Hb ≥110 g/L (when pretreatment Hb was \<100g/L), confirmed in two blood tests separated a minimum of 7 days. Participants who discontinued before Week 16 were considered as responders if, in the last evaluation, they had PR or CR. The 95% Confidence Interval (CI) was the binomial exact CI based on Clopper-Pearson method.

Time frame:
Baseline up to Week 16
Reported as:
Number · Percentage of participants
Hematologic Response Rate by 16 Weeks After the Initiation of Eltrombopag
Percentage of participantsEltrombopag
Hematologic Response Rate by 16 Weeks After the Initiation of Eltrombopag40.0 (12.2 to 73.8)
SecondaryPercentage of Participants Who Had a Response in the Neutrophil Lineage

Percentage of participants who had a response (partial or complete) in the neutrophil lineage. A partial response in the neutrophil lineage was defined as absolute neutrophil count (ANC) ≥1000/ µL (when pretreatment ANC was \<1000/μL) confirmed in two consecutive blood tests separated a minimum of 7 days. A complete response in the neutrophil lineage was defined as ANC ≥ 1500/ µL (when pretreatment ANC was \<1000/μL) confirmed in two consecutive blood tests separated a minimum of 7 days. The 95% CI was the binomial exact CI based on Clopper-Pearson method

Time frame:
Week 16, 20, 24, 30 and 36
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had a Response in the Neutrophil Lineage
Percentage of ParticipantsEltrombopag
Week 16100 (NA to NA)
Week 20100 (NA to NA)
Week 24100 (NA to NA)
Week 30100 (NA to NA)
Week 36100 (NA to NA)
SecondaryPercentage of Participants Who Had a Response in the Platelet Lineage

Percentage of participants who had a response (partial or complete) in the platelet lineage. A partial response in the platelet lineage was defined as platelet count ≥20000/µL (with platelet transfusion independence) confirmed in two consecutive blood tests separated a minimum of 7 days. A complete response in the platelet lineage was defined as platelet count ≥ 100000/µL confirmed in two consecutive blood tests separated a minimum of 7 days. The 95% CI was the binomial exact CI based on Clopper-Pearson method.

Time frame:
Week 16, 20, 24, 30 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Who Had a Response in the Platelet Lineage
Percentage of participantsEltrombopag
Week 1666.7 (22.3 to 95.7)
Week 2066.7 (22.3 to 95.7)
Week 2483.3 (35.9 to 99.6)
Week 30100 (NA to NA)
Week 36100 (NA to NA)
SecondaryPercentage of Participants Who Had a Response in the Hemoglobin Lineage

Percentage of participants who had a response (partial or complete) in the hemoglobin (Hb) lineage. A partial response in the Hb lineage was defined as Hb ≥100 g/L (when pretreatment Hb was \<100g/L) (with RBC transfusion independence), confirmed in two consecutive blood tests separated a minimum of 7 days. A complete response in the Hb lineage was defined as Hb≥ 110 g/L (when pretreatment Hb was \<100g/L) confirmed in two consecutive blood tests separated a minimum of 7 days. The 95% CI was the binomial exact CI based on Clopper-Pearson method.

Time frame:
Week 16, 20, 24, 30 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Who Had a Response in the Hemoglobin Lineage
Percentage of participantsEltrombopag
Week 1660.0 (14.7 to 94.7)
Week 2060.0 (14.7 to 94.7)
Week 2480.0 (28.4 to 99.5)
Week 30100 (NA to NA)
Week 36100 (NA to NA)
SecondaryHematologic Response Rate at Week 24 and 36

Hematologic response rate was defined as the percentage of participants who met the criteria of either complete response (CR) or partial response (PR) at 24 weeks and 36 weeks after the initiation of eltrombopag. PR was defined when any of the following: Platelet count ≥20000/microliter (μL) (with platelet transfusion independence), absolute neutrophil count (ANC) ≥1000/μL (when pretreatment ANC was \<1000/μL) and/or hemoglobin (Hb) ≥100 gram (g)/ liter (L) (when pretreatment Hb was \<100g/L) (with red blood cells transfusion independence), confirmed in two blood tests separated a minimum of 7 days. CR was defined when all three of the following: platelet count ≥100000/μL, ANC ≥1500/μL (when pretreatment ANC was \<1000/μL) and Hb ≥110 g/L (when pretreatment Hb was \<100g/L), confirmed in two blood tests separated a minimum of 7 days. The 95% CI was the binomial exact CI based on Clopper-Pearson method.

Time frame:
Week 24 and 36
Reported as:
Number · Percentage of participants
Hematologic Response Rate at Week 24 and 36
Percentage of participantsEltrombopag
Week 2483.3 (35.9 to 99.6)
Week 36100 (NA to NA)
SecondaryPercentage of Participants Who Were Previously Platelet Transfusion-dependent and Did no Longer Require Platelet Transfusions After the Initiation of Eltrombopag

Percentage of participants who received at least one platelet transfusion before starting treatment and who did no longer require platelet transfusion before and after the first 16 weeks of treatment. The 95% CI was the binomial exact CI based on Clopper-Pearson method.

Time frame:
From start of treatment to end of treatment, assessed up to 36 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were Previously Platelet Transfusion-dependent and Did no Longer Require Platelet Transfusions After the Initiation of Eltrombopag
Percentage of participantsEltrombopag
From start of treatment to Week 160 (NA to NA)
From Week 16 to end of treatment66.7 (9.4 to 99.2)
SecondaryPercentage of Participants Who Were Previously Red Blood Cells Transfusion-dependent and Did no Longer Require Red Blood Cells Transfusions

Percentage of participants who received at least one red blood cells transfusion before starting treatment and who did no longer require red blood cells transfusion before and after the first 16 weeks of treatment. The 95% CI was the binomial exact CI based on Clopper-Pearson method.

Time frame:
From start of treatment to end of treatment, assessed up to 36 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were Previously Red Blood Cells Transfusion-dependent and Did no Longer Require Red Blood Cells Transfusions
Percentage of participantsEltrombopag
From start of treatment to Week 1616.7 (0.42 to 64.1)
From Week 16 to end of treatment50 (1.2 to 98.7)
SecondaryDuration of Transfusion Independence

Duration of transfusion independence defined as the period of time where participants did not receive any platelet or red blood cells transfusions during the treatment period

Time frame:
From start of treatment to end of treatment, assessed up to 36 weeks
Reported as:
Mean · Days
Duration of Transfusion Independence
DaysEltrombopag
Duration of Transfusion Independence137.7 ± 110.4
SecondaryPercentage of Participants Who Discontinued or Reduced the Use of Concomitant Erythropoietin (EPO) Therapy

Percentage of participants who discontinued or reduced by ≥50% from baseline the use of concomitant EPO therapy while receiving eltrombopag. The 95% CI was the binomial exact CI based on Clopper-Pearson method.

Time frame:
From start of treatment to end of treatment, assessed up to Week 36
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued or Reduced the Use of Concomitant Erythropoietin (EPO) Therapy
Percentage of participantsEltrombopag
Discontinued EPO therapy37.5 (8.5 to 75.5)
Reduced by 50% EPO therapy0 (NA to NA)
SecondaryPercentage of Participants Who Discontinued or Reduced the Use of Concomitant Granulocyte Colony-stimulating Factor (G-CSF) Therapy

Percentage of participants who discontinued or reduced by ≥50% from baseline the use of concomitant G-CSF therapy while receiving eltrombopag. The 95% CI was the binomial exact CI based on Clopper-Pearson method.

Time frame:
From start of treatment to end of treatment, assessed up to Week 36
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued or Reduced the Use of Concomitant Granulocyte Colony-stimulating Factor (G-CSF) Therapy
Percentage of participantsEltrombopag
Discontinued G-CSF therapy85.7 (42.1 to 99.7)
Reduced by 50% G-CSF therapy0 (NA to NA)
SecondaryOverall Survival (OS)

OS defined as the time from the date of inclusion until the date of death due to any cause was calculated using Kaplan-Meier estimated. All patients who discontinued from the study, regardless the reason of discontinuation, were followed for survival, unless they withdrew their consent, died or were lost-to follow-up, in which case were censored at the last contact.

Time frame:
From start of treatment until the date of death, assessed up to 40 weeks
Reported as:
Median · Weeks
Overall Survival (OS)
WeeksEltrombopag
Overall Survival (OS)NA ± NA
SecondaryOverall Survival Rate at 24 and 36 Weeks

Overall survival rate defined as the rate estimate of the percentage of participants who were alive at 24 and 36 weeks. All patients who discontinued from the study, regardless the reason of discontinuation, were followed for survival at Week 24 and 36, unless they withdrew their consent, died or were lost-to follow-up, in which case were censored at the last contact.

Time frame:
Week 24 and 36
Reported as:
Number · Percentage of participants
Overall Survival Rate at 24 and 36 Weeks
Percentage of participantsEltrombopag
Week 2490.0 (71.4 to 100.0)
Week 3680.0 (52.5 to 100.0)
Post-hocAll Collected Deaths

On-treatment deaths due to any cause were collected from first dose of study medication to 30 days after the last dose of eltrombopag. Post-treament survival follow-up deaths were collected from day 31 after last dose of study medication to end of study. Participants who completed treatment with study drug as planned at Week 36, were followed up until Week 40 and deaths that occurred within that time frame were counted as on-treatment. For all participants who discontinued from eltrombopag, post-treatment deaths due to any cause were collected after the on-treatment period until end of survival follow-up period.

Time frame:
On-treatment deaths: Up to 40 weeks. Post-treatment survival follow-up deaths: up to 40 weeks
Reported as:
Count of participants · Participants
All Collected Deaths
ParticipantsEltrombopag
On-treatment deaths0
Post-treatment survival follow-up deaths2
All deaths2

Adverse events

Collected over From day of first dose of study medication to the last dose of study medication plus 30 days, up to 40 weeks. Deaths were collected in the post treatment survival follow up from 31 days after last dose of study medication until the end of the study, up to 40 weeks. These are not considered AEs. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag (On-treatment)0/10 (0%)3/10 (30%)10/10 (100%)
Eltrombopag (Post-treatment Survival Follow-up)2/7 (28.6%)——
Most frequent serious events
Most frequent serious events
EventEltrombopag (On-treatment)Eltrombopag (Post-treatment Survival Follow-up)
Febrile neutropeniaBlood and lymphatic system disorders1/10—
Urinary tract obstructionRenal and urinary disorders1/10—
ChimerismCongenital, familial and genetic disorders1/10—
Epstein-Barr virus infection reactivationInfections and infestations1/10—
Escherichia urinary tract infectionInfections and infestations1/10—
PyrexiaGeneral disorders1/10—
UrosepsisInfections and infestations1/10—
Most frequent other events
Showing 10 of 37
Most frequent other events
EventEltrombopag (On-treatment)Eltrombopag (Post-treatment Survival Follow-up)
NauseaGastrointestinal disorders4/10—
AstheniaGeneral disorders3/10—
RashSkin and subcutaneous tissue disorders3/10—
Decreased appetiteMetabolism and nutrition disorders2/10—
Iron overloadMetabolism and nutrition disorders2/10—
NasopharyngitisInfections and infestations2/10—
CoughRespiratory, thoracic and mediastinal disorders2/10—
NeutropeniaBlood and lymphatic system disorders2/10—
Upper respiratory tract infectionInfections and infestations2/10—
Breast painReproductive system and breast disorders1/10—

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Eltrombopag
Median52.5 (23.0 to 72.0)
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag
Female4
Male6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Eltrombopag
Caucasian9
Native American1
08

Study locations

7 sites
  • Novartis Investigative Site
    Malaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Salamanca, Castilla Y Leon 37007, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46010, Spain
  • Novartis Investigative Site
    Palma De Mallorca, Islas Baleares 07120, Spain
  • Novartis Investigative Site
    San Sebastian, Pais Vasco 20080, Spain
  • Novartis Investigative Site
    Vigo, Pontevedra 36212, Spain
  • Novartis Investigative Site
    Barcelona, 08041, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Nov 2020, 22 months.

Results were first posted in Feb 2024, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2018
First posted
Oct 24, 2018
StartActual
Dec 17, 2018
Primary completionActual
Nov 3, 2020
CompletionActual
Nov 3, 2020
Results first posted
Feb 5, 2024
Last update
Feb 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03718533
Responsible party
Sponsor
First posted
Oct 24, 2018
Start date
Dec 17, 2018
Primary completion
Nov 3, 2020
Completion
Nov 3, 2020
Results posted
Feb 5, 2024
Last update
Feb 29, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion